Page 9 - Plasma Profile

CHAIRMAN

STATEMENT

We deliver value rather than products. Each
segment we serve is developed looking deep
in to the customer's desire and their choice.

We believe the strategy we adopted in both of
our divisions is proving to be correct. In
particular, the COVID-19 pandemic has
demonstrated the value of our solutions that
help with the containment of infectious
disease outbreaks – namely, our NATlab
diagnostic system, which can identify human
pathogens with unparalleled speed and
accuracy, and our Eco-Med products for
pathogenic waste treatment. At the same
time, the importance of secure, virtual
networks has never been more apparent.

In 2019, we achieved the goals that we
set for ourselves for the year. We delivered
growth in revenue to $123.4m (2018:
$119.6m) and adjusted operating profit was
$5.3m (2018: $2.6m). We saw meaningful
progression in NFV and molecular diagnostics
– our key future growth markets. We are also
pleased with the solid commercial traction
that we have established in our Eco-Med and
Cyber businesses. We gained new customers
and partners, secured new contracts,
expanded into new territories and continued
to establish a leading position in our target
markets.

SURESH C.P.

www.plasmaventuresllp.in 09